A novel option for prandial insulin therapy: inhaled insulin

References

• IDF diabetes atlas. 6th ed. Brussels (Belgium): International Diabetes Federation; 2013.
   Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
   PubMed Web of Science ®Google Scholar
• Nathan DM, DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37:9–16.
   PubMed Web of Science ®Google Scholar
• Rendell MS, Jovanovic L. Targeting postprandial hyperglycemia. Metabolism. 2006;55:1263–1281.
   PubMed Web of Science ®Google Scholar
• Cavalot F, Pagliarino A, Valle M, et al. Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study. Diabetes Care. 2011;34:2237–2243.
   PubMed Web of Science ®Google Scholar
• Clark NG. Postprandial blood glucose, cardiovascular events, and all-cause mortality: how do we use postprandial glucose in clinical practice? Clin Diabetes. 2012;30:67–69.
   Google Scholar
• Mata-Cases M, Mauricio D, Franch-Nadal J. Clinical characteristics of type 2 diabetic patients on basal insulin therapy with adequate fasting glucose control who do not achieve HbA1c targets. J Diabetes. 2016 Jan 8. doi:10.1111/1753-0407.12373. [Epub ahead of print].
   Google Scholar
• Gordin D, Saraheimo M, Tuomikangas J, et al. Influence of postprandial hyperglycemic conditions on arterial stiffness in patients with type 2 diabetes. J Clin Endocrinol Metab. 2016;101:1134–1143.
   PubMed Web of Science ®Google Scholar
• Cavalot F. Do data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetes. Diabetes Obes Metab. 2013;15(Suppl 2):3–8.
   PubMed Web of Science ®Google Scholar
• Sartore G, Chilelli NC, Burlina S, et al. Association between glucose variability as assessed by continuous glucose monitoring (CGM) and diabetic retinopathy in type 1 and type 2 diabetes. Acta Diabetol. 2013;50:437–442.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2016 Executive Summary. Endocr Pract. 2016;22:84–113.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JM, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149.
   PubMed Web of Science ®Google Scholar
• Schrot RJ. Targeting plasma glucose: preprandial versus postprandial. Clin Diabetes. 2004;22:169–172.
   Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–1379.
   PubMed Web of Science ®Google Scholar
• Subramanian S, Hirsch IB. Personalized diabetes management: moving from algorithmic to individualized therapy. Diabetes Spectr. 2014;27:87–91.
   PubMedGoogle Scholar
• Riddle MC. The transition from oral agents to combination insulin/oral therapy. In: Feinglos MN, Bethel MA, editors. Contemporary endocrinology: Type 2 diabetes mellitus: an evidence-based approach to practical management. Totowa (NJ): Humana Press; 2008. p. 169–181.
   Google Scholar
• Polonsky WH, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes. The scope of the problem. Diabetes Care. 2005;28:2543–2545.
   PubMed Web of Science ®Google Scholar
• Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers. Results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study. Diabetes Care. 2005;28:2673–2679.
   PubMed Web of Science ®Google Scholar
• Kugler AJ, Fabbio KL, Pham DQ, et al. Inhaled technosphere insulin: a novel delivery system and formulation for the treatment of types 1 and 2 diabetes mellitus. Pharmacotherapy. 2015;35:298–314.
   PubMed Web of Science ®Google Scholar
• Heise T, Meneghini LF. Insulin stacking versus therapeutic accumulation: understanding the differences. Endocr Pract. 2014;20:75–83.
   PubMed Web of Science ®Google Scholar
• US FDA. Press Announcements: FDA approves Afrezza to treat diabetes; [cited 2014 Jun 27; updated 2015 Dec 17]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm403122
   Google Scholar
• Kokić S, Buković D, Radman M, et al. Lispro insulin and metformin versus other combination in the diabetes mellitus type 2 management after secondary oral antidiabetic drug failure. Coll Antropol. 2003;27:181–187.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Zinman B, Murphy LJ, et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2005;143:549–558.
   PubMed Web of Science ®Google Scholar
• Pala L, Mannucci E, Dicembrini I, et al. A comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patients. Diabetes Res Clin Pract. 2007;78:132–135.
   PubMed Web of Science ®Google Scholar
• Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357:1716–1730.
   PubMed Web of Science ®Google Scholar
• Yamashiro K, Ikeda F, Fujitani Y, et al. Comparison of thrice-daily lispro 50/50 vs thrice-daily lispro in combination with sulfonylurea as initial insulin therapy for type 2 diabetes. J Diabetes Investig. 2010;1:149–153.
   PubMed Web of Science ®Google Scholar
• Brunton SA. Hypoglycemic potential of current and emerging pharmacotherapies in type 2 diabetes mellitus. Postgrad Med. 2012;124:74–83.
   PubMed Web of Science ®Google Scholar
• Hamnvik OP, McMahon GT. Balancing risk and benefit with oral hypoglycemic drugs. Mt Sinai J Med. 2009;76:234–243.
   PubMedGoogle Scholar
• Du YF, Ou HY, Beverly EA, et al. Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options. Clin Interv Aging. 2014;9:1963–1980.
   PubMed Web of Science ®Google Scholar
• Phillips P. Type 2 diabetes - failure, blame and guilt in the adoption of insulin therapy. Rev Diabet Stud. 2005;2:35–39.
   PubMedGoogle Scholar
• Peyrot M, Rubin RR, Kruger DF, et al. Correlates of insulin injection omission. Diabetes Care. 2010;33:240–245.
   PubMed Web of Science ®Google Scholar
• Peyrot M, Barnett AH, Meneghini LF, et al. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012;29:682–689.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Gagliardino JJ, Gray LJ, et al. Real-world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review. Diabet Med. 2013;30:512–524.
   PubMed Web of Science ®Google Scholar
• Donnelly LA, Morris AD, Evans JM, et al. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM. 2007;100:345–350.
   PubMed Web of Science ®Google Scholar
• García-Pérez LE, Alvarez M, Dilla T, et al. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4:175–194.
   PubMed Web of Science ®Google Scholar
• Sarala N, Bengalorkar G, Bhuvana K. Technosphere: new drug delivery system for inhaled insulin. Fut Prescriber. 2012;13:14–16.
   Google Scholar
• Cassidy JP, Amin N, Marino M, et al. Insulin lung deposition and clearance following Technosphere Insulin inhalation powder administration. Pharm Res. 2011;28:2157–2164.
   PubMed Web of Science ®Google Scholar
• Ledet G, Graves RA, Bostanian LA, et al. A second-generation inhaled insulin for diabetes mellitus. Am J Health Syst Pharm. 2015;72:1181–1187.
   PubMed Web of Science ®Google Scholar
• Marino MK, Cassidy JP, Smutney CC, et al. Bioequivalence and dose proportionality of AFREZZA® inhalation powder administered using a Gen2 inhaler compared to the Medtone® inhaler. Presented at the Diabetes Technology Meeting; 2010 Nov 11–13; Bethesda (MD). Poster #142. Available from: http://www.mannkindcorp.com/collateral/documents/english-us/2010-dts-poster-142-be-final-lr-11.10.10.pdf.
   Google Scholar
• Tibaldi JM. Evolution of insulin: from human to analog. Am J Med. 2014;127(10 Suppl):S25–38.
   PubMed Web of Science ®Google Scholar
• Rave K, Potocka E, Heinemann L, et al. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab. 2009;11:715–720.
   PubMed Web of Science ®Google Scholar
• Rave K, Heise T, Heinemann L, et al. Inhaled Technosphere insulin in comparison to subcutaneous regular insulin: time action profile and variability in subjects with type 2 diabetes. J Diabetes Sci Technol. 2008;2:205–212.
   PubMedGoogle Scholar
• Humalog Prescribing Information. 2015 [cited 2015 Dec 17]. Available from: http://pi.lilly.com/us/humalog-pen-pi.pdf
   Google Scholar
• Apidra Prescribing Information. 2009 [cited 2015 Dec 17]. Available from: http://medconnections.com/drugs/pdf/apidra.pdf
   Google Scholar
• Novalog Prescribing Information. 2010 [cited 2015 Dec 17]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM214655.pdf
   Google Scholar
• Afrezza Prescribing Information. 2014 [cited 2015 Dec 17]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022472lbl.pdf
   Google Scholar
• Rosenstock J, Bergenstal R, Defronzo RA, et al. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents. Diabetes Care. 2008;31:2177–2182.
   PubMed Web of Science ®Google Scholar
• Rendell M. Technosphere inhaled insulin (Afrezza). Drugs Today (Barc). 2014;50:813–827.
   PubMed Web of Science ®Google Scholar
• Raskin P, Heller S, Honka M, et al. Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: a randomized trial. Diabetes Obes Metab. 2012;14:163–173.
   PubMed Web of Science ®Google Scholar
• US FDA. Briefing Document: Endocrinologic and Metabolic Drugs Advisory Committee Meeting, April 1, 2014 [cited 2015 Dec 17]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM390864.pdf
   Google Scholar
• Bode BW, McGill JB, Lorber DL, et al. Inhaled Technosphere insulin compared with injected prandial insulin in type 1 diabetes: a randomized 24-week trial. Diabetes Care. 2015;38:2266–2273.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Lorber DL, Gnudi L, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet. 2010;375:2244–2253.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Franco D, Korpachev V, et al. Inhaled Technosphere insulin versus inhaled Technosphere placebo in insulin-naïve subjects with type 2 diabetes inadequately controlled on oral antidiabetes agents. Diabetes Care. 2015;38:2274–2281.
   PubMed Web of Science ®Google Scholar
• Pittas AG, Westcott GP, Balk EM. Efficacy, safety, and patient acceptability of Technosphere inhaled insulin for people with diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3:886–894.
   PubMed Web of Science ®Google Scholar
• Muchmore DB, Vaughn DE. Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase. J Diabetes Sci Technol. 2012;6:764–772.
   PubMedGoogle Scholar
• Zisser H, Jovanovic L, Markova K, et al. Technosphere insulin effectively controls postprandial glycemia in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2012;14:997–1001.
   PubMed Web of Science ®Google Scholar
• Peyrot M, Rubin RR. Effect of technosphere inhaled insulin on quality of life and treatment satisfaction. Diabetes Technol Ther. 2010;12:49–55.
   PubMed Web of Science ®Google Scholar
• Tack CJ, Christov V, de Galan BE, et al. Randomized forced titration to different doses of technosphere insulin demonstrates reduction in postprandial glucose excursions and hemoglobin A1c in patients with type 2 diabetes. J Diabetes Sci Technol. 2008;2:47–57.
   PubMedGoogle Scholar
• Sanofi-Aventis US. Dosing Guide for Afrezza®. 2015 [cited 2016 Jan 6]. Available from: http://hcp.afrezza.com/AfrezzaConfigurationChart.pdf
   Google Scholar